Men with prostate cancer who take cholesterol-lowering drugs called statins are significantly less likely to die from their cancer than men who don't take such medication, according to a study led by Dr. Janet Stanford and colleagues in the Hutchinson Center's Public Health Sciences Division. The findings came out online May 1 in The Prostate.
The study followed about a thousand Seattle-area prostate cancer patients, approximately 30 percent of whom reported using statin drugs to control their cholesterol. After a mean follow-up of almost eight years, the researchers found the risk of death from prostate cancer among statin users was 1 percent as compared to 5 percent for nonusers.
"If the results of our study are validated in other patient cohorts with extended follow-up for cause-specific death, an intervention trial of statin drugs in prostate cancer patients may be justified," said Stanford, co-director of the Center's Prostate Cancer Research Program.
"While statin drugs are relatively well tolerated with a low frequency of serious side effects, they cannot be recommended for the prevention of prostate cancer-related death until a preventive effect on mortality from prostate cancer has been demonstrated in a large, randomized, placebo-controlled clinical trial," said first author Milan Geybels, formerly a researcher in Stanford's group, now a doctoral candidate at Maastricht University in the Netherlands.
The study is unique in that most prior research of the impact of statin use on prostate cancer outcomes has focused on biochemical recurrence—a rising PSA level—and not prostate cancer-specific mortality. "Very few studies of statin use in relation to death from prostate cancer have been conducted, possibly because such analyses require much longer follow-up for the assessment of this prostate cancer outcome," Geybels said.
The potential biological explanation behind the association between statin use and decreased mortality from prostate cancer may be related to cholesterol- and non-cholesterol-mediated mechanisms:
"Prostate cancer is an interesting disease for which secondary prevention, or preventing poor long-term patient outcomes, should be considered because it is the most common cancer among men in developed countries and the second leading cause of cancer-related deaths," Geybels said. "While many prostate cancer patients have indolent, slow-growing tumors, others have aggressive tumors that may recur or progress to a life-threatening disease despite initial therapy with radiation or surgery. Therefore, any compound that could stop or slow the progression of prostate cancer would be beneficial," he said.
Other PHS co-authors on the paper were Suzanne Kolb and Drs. Jonathan Wright, Sarah Holt and Ziding Feng.
The National Cancer Institute, a grant from the Dutch Cancer Society and additional support from Fred Hutchinson Cancer Research Center and the Prostate Cancer Foundation funded the research.